Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation
AssigneeThomas Jefferson University
InventorsJoel Rosenbloom, Edward John Macarak
Life of this patent
Estimating the term…
Abstract
A method of reducing the severity of abdominal adhesion due to surgical complications comprising: administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, and after said surgical procedure, administering to said patient a further dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery.
Claims26
A method of reducing the occurrence of abdominal adhesions in a patient undergoing a surgical procedure comprising administering to said patient an effective dose of trametinib, sufficient to reduce the formation of an adhesion.
A method of reducing the severity of abdominal adhesion due to surgical complications comprising:
- administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, and after said surgical procedure, administering to said patient a further dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery.
A method of reducing the severity of abdominal adhesion after a surgical procedure comprising:
- administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery.
An animal model which can be used to test drugs effective in blocking pathways regulating ECM deposition associated with adhesion formation.
A method of treating a patient for development of excessive fibrin formation comprising;
- administering to a patient an effective amount of trametinib suitable to treat said fibrin formation;
- taking a biopsy from said patient in an area of possibly fibrin formation and detecting for the presence of alpha SMA and FNEDA;
- determining the levels of alpha SMA or FNEDA to confirm the presence or absence of the presence of myofibroblasts;
- administering at least an additional second dose of trametinib when alpha SMA or FNEDA are detected in the sample.
A method of treating fibrosis comprising:
- taking a biopsy from a patient suspected to have fibrosis;
- determining the presence of Alpha SMA or FNEDA, administering to said patient an effective amount of trametinib when the presence of Alpha SMA or FNEDA are confirmed in the biopsy sample.
A method of treating pulmonary fibrosis comprising administering to a patient suffering from or susceptible to formation of pulmonary fibrosis an effective amount of trametinib.
A method of reducing the formation of pulmonary fibrosis comprising administering to a patient an effective amount of trametinib, wherein said effective amount is between 0.01 mg to 2.0 mg.
Dependencies are inferred from the claim text.